Abeona Therapeutics Inc. last reported quarterly results on Aug 13, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $11.4 million (+2745.0% year over year) and diluted EPS of -$0.35. It usually reports 2–44 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 11, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Nov 12, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 2–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 13, 2026
44 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
11
+2745.0%
|
-20
-118.6%
|
-0.35
-120.5%
|
|
May 13, 2026
43 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
9
|
-17
-41.9%
|
-0.30
-25.0%
|
|
Nov 12, 2025
43 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
0
|
-5
+82.9%
|
-0.10
+84.1%
|
|
Jul 2, 2025
2 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
0
-88.6%
|
109
+1369.5%
|
1.71
+757.7%
|
|
May 15, 2025
45 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
—
|
-12
+61.9%
|
-0.24
+79.3%
|
|
Nov 14, 2024
45 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
—
|
-30
-155.7%
|
-0.63
-31.3%
|
|
Aug 12, 2024
43 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
|
May 3, 2024
33 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABEO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cleveland, OH
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 318306
- Former names
- PLASMATECH BIOPHARMACEUTICALS INC (until Jun 4, 2015); ACCESS PHARMACEUTICALS INC (until Aug 14, 2014); CHEMEX PHARMACEUTICALS INC (until Feb 5, 1996)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.